Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
37
datasets available to search
ShareScore release 0.9.0
Dataset results
37 results for “polymyxin B”
Dataset for: The antibacterial activity of peptide dendrimers and polymyxin B increases sharply above pH 7.4
<p>The upload contains additional primary data associated with the publication, including raw data in the original file format whenever possible.</p> <p>Data content: HRMS, HPLC-MS, pH titration, CD, MD, TEM</p> <p> </p>
The Effects of Polymyxin-B Protects on Sepsis Induced Kidney Dysfunction: a Randomized Clinical Trial
ClinicalTrials.gov study NCT00490477. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock
ClinicalTrials.gov study NCT01046669. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Data from: Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: A retrospective cohort study
<p><strong>Purpose:</strong> Infection by carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP) has high mortality. There is no clear optimal therapeutic choice for pneumonia caused by CRKP. The aim of this study was to compare the clinical outcomes and safety of the standard doses of polymyxin B-based regimens vs tigecycline-based regimens and to identify risk factors for mortality.</p> <p><strong>Methods:</strong><strong> </strong>This retrospective cohort study included patients with pneumonia caused by CRKP for three years. The primary outcomes were 7-day bacterial eradication rate and 14- and 28-day all-cause mortality. The secondary outcome was incidence of acute kidney injury.</p> <p><strong>Results:</strong><strong> </strong>Seventy-three patients were included in this study, 29 in the<strong> </strong>polymyxin B-based combination therapy group and 44 in tigecycline-based combination therapy group. There were no significant differences between the two groups in terms of the 7-day bacterial eradication rate (31.0% vs 20.5%, <em>P</em>=0.409), the 14-day all-cause mortality (37.9% vs 22.7%, <em>P</em>=0.160), and the incidence of acute kidney injury (14.3% vs 6.8%, <em>P</em>=0.526). The 28-day all-cause mortality in the polymyxin B-based therapy group was higher than in the tigecycline-based group (75.9% vs 45.5%, <em>P</em>=0.010). Binary logistic regression analysis revealed that male and previous use of carbapenems were independent factors associated with 28-day all-cause mortality for patients treated with polymyxin B (<em>P</em><0.05).</p> <p><strong>Conclusions:</strong><strong> </strong>Polymyxin B-based combination therapy at the standard dose should be used with caution for patients with CRKP-induced pneumonia, especially for men who used carbapenems prior to CRKP detection.</p>
Preliminary Investigation of Side Effects of Polymyxin B Administration in Hospitalized Horses
<p>Data set to the publication: https://doi.org/10.3390/antibiotics12050854</p>
Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock
ClinicalTrials.gov study NCT01222663. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Polymyxin B Monotherapy vs Combination Therapy in Critically Ill Patients With Multi-drug Resistant Pathogens
ClinicalTrials.gov study NCT03159078. IPD Sharing: NO. Countries: 1. Publications: 21.
Early Use of Polymyxin B Hemoperfusion in Abdominal Sepsis
ClinicalTrials.gov study NCT00629382. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Pharmacokinetics of Polymyxin B in Adult Patients With Cystic Fibrosis
ClinicalTrials.gov study NCT04335370. IPD Sharing: NO. Countries: 1. Publications: 1.
The Pilot Study of the Efficacy of Polymyxin-B Hemoperfusion in Critically Ill Patients With Severe Sepsis
ClinicalTrials.gov study NCT02413541. IPD Sharing: Not stated. Countries: 1. Publications: 2.
A Pharmacokinetic Study of Polymyxin B in Healthy Subjects and Subjects With Renal Insufficiency
ClinicalTrials.gov study NCT05359627. IPD Sharing: NO. Countries: 1. Publications: 0.
Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study
ClinicalTrials.gov study NCT03901807. IPD Sharing: NO. Countries: 1. Publications: 1.
The Effects of a Polyethyleneimine-coated Membrane (oXiris™) for Hemofiltration Versus Polymyxin B- Immobilized Fibre Column (Toraymyxin™) for Hemoperfusion on Endotoxin Activity and Inflammatory Cond
ClinicalTrials.gov study NCT01948778. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Efficacy of Polymyxin B Against Infections Caused by Extensively Drug-resistant (XDR) Gram-Negative Bacteria
ClinicalTrials.gov study NCT02328183. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Data from: Clinical outcomes and safety of polymyxin B versus tigecycline combination therapy for pneumonia of carbapenem-resistant Klebsiella pneumoniae: A retrospective cohort study
Open the record for dataset details and reuse information.
identification by RNA-Seq of PhoP and polymyxin B resistant regulons in Photorhabdus luminescens TT01.
GEO Series GSE76559. Photorhabdus laumondii subsp. laumondii TTO1. 12 samples. Type: Expression profiling by high throughput sequencing.
High-throughput Fitness Experiments Reveal Specific Vulnerabilities of Human-Adapted Salmonella During Stress and Infection- Barseq9 (LB, gentamycin, cotrimoxazole, rifampicin, polymyxin B)
GEO Series GSE262848. Salmonella enterica subsp. enterica serovar Typhimurium str. D23580; Salmonella enterica subsp. enterica serovar Paratyphi A str. ATCC 9150; Salmonella enterica subsp. enterica serovar Typhimurium str. ST4/74; Salmonella enterica subsp. enterica serovar Typhi str. Ty2. 48 samples. Type: Other.
Drug efflux and lipid A modification by 4-L-aminoarabinose are key mechanisms of polymyxin B resistance in the sepsis pathogen Enterobacter bugandensis
GEO Series GSE218614. Enterobacter cloacae. 12 samples. Type: Expression profiling by high throughput sequencing.
A plant-derived antimicrobial peptide with multiple mechanisms of action exhibiting antibacterial and antibiofilm activities comparable to or superior to polymyxin B
GEO Series GSE312438. Escherichia coli. 6 samples. Type: Expression profiling by high throughput sequencing.
Data from: Oral administration of Polymyxin B modulates the activity of Lipooligosaccharide E. coli B against lung metastases in murine tumor models
Introduction: Polymyxin B (PmB) belongs to the group of cyclic peptide antibiotics, which neutralize the activity of LPS by binding to lipid A. The aim of this study was to analyze the effect of PmB on the biological activity of lipooligosaccharide (LOS E. coli B,rough form of LPS) in vitro and in experimental metastasis models. Results: Cultures of murine macrophage J774A.1 cells and murine bone marrow-derived dendritic cells (BM-DC) stimulated in vitro with LOS and supplemented with PmB demonstrated a decrease in inflammatory cytokine production (IL-6, IL-10, TNF-α) and down-regulation of CD40, CD80, CD86 and MHC class II molecule expression. Additionally, PmB suspended in drinking water was given to the C57BL/6 mice seven or five days prior to the intravenous injection of B16 or LLC cells and intraperitoneal application of LOS. This strategy of PmB administration was continued throughout the duration of the experiments (29 or 21 days). In B16 model, statistically significant decrease in the number of metastases in mice treated with PmB and LOS (p<0.01) was found on the 14th day of the experiments, whereas the most intensive changes in surface-antigen expression and ex vivo production of IL-6, IL-1β and TNF-α by peritoneal cells were observed 7 days earlier. By contrast, antigen expression and ex vivo production of IL-6, IL-10, IFN-γ by splenocytes remained relatively high and stable. Statistically significant decrease in LLC metastases number was observed after the application of LOS (p<0.01) and in the group of mice preconditioned by PmB and subsequently treated with LOS (LOS + PmB, p<0.01). Conclusions: In conclusion, prolonged in vivo application of PmB was not able to neutralize the LOS-induced immune cell activity but its presence in the organism of treated mice was important in modulation of the LOS-mediated response against the development of metastases.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.